Latest Phenols Stories
TORONTO, March 26, 2015 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX:TTH) today announced results from two phase 1 clinical studies
--Company to host conference call today at 8:00 AM EDT-- WAYNE, Pa., March 25, 2015 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical
Enteric-Coated Buprenorphine Product Candidates (BuTab, REL-1028) to be Compared with Marketed Intravenous and Sublingual Formulations NEW YORK, March 24, 2015 /PRNewswire/ -- Relmada
A new form of Naltrexone, Vivitrol, has been proven effective in treating nearly every patient prescribed the opiate blocking medication by the Washington County Health Department, according to
AcelRx Announces Restructuring to Focus on Regulatory Approval of Zalviso and Clinical Development of ARX-04 REDWOOD CITY, Calif., March 20, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
Harbor Village Detox comments on the effectiveness of naltrexone, which is a non opiate based drug helping drug addicts to overcome heroin addiction and opiate abuse.
NEWARK, Calif., March 17, 2015 /PRNewswire/ -- Depomed, Inc.
Novel product candidate being developed for the treatment of neuropathic pain demonstrates good safety profile even at higher doses NEW YORK, March 17, 2015 /PRNewswire/ -- Relmada
--Shionogi's S-718632 investigational new drug application was submitted and is open-- WAYNE, Pa., March 17, 2015 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully
WAYNE, Pa., March 16, 2015 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet") today reported financial results for the year ended December 31, 2014.
More Images (1 images) »